Modulation of GITR for cancer immunotherapy.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Current Opinion in Immunology

• Publication date

  2012-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.coi.2011.12.011PMID 22245556PMCID PMC3413251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GITR Gene Deletion and GITR-Fc Soluble Protein Administration Inhibit Multiple Organ Failure Induced by Zymosan

  2011cited by this paper
• Science gone translational: the OX40 agonist story

  2011cited by this paper
• Enhancement of anti‐tumor immunity through local modulation of CTLA‐4 and GITR by dendritic cells

  2011cited by this paper
• T‐cell intrinsic effects of GITR and 4‐1BB during viral infection and cancer immunotherapy

  2011cited by this paper
• Combination CTLA-4 Blockade and 4-1BB Activation Enhances Tumor Rejection by Increasing T-Cell Infiltration, Proliferation, and Cytokine Production

  2011cited by this paper
• CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

  2011cited by this paper
• Stimulation of the Glucocorticoid-Induced TNF Receptor Family-Related Receptor on CD8 T Cells Induces Protective and High-Avidity T Cell Responses to Tumor-Specific Antigens

  2011cited by this paper
• Th2 Responses to Helminth Parasites Can Be Therapeutically Enhanced by, but Are Not Dependent upon, GITR–GITR Ligand Costimulation In Vivo

  2011cited by this paper
• The glucocorticoid‐induced TNF receptor family‐related protein (GITR) is critical to the development of acute pancreatitis in mice

  2011cited by this paper
• Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy

  2010cited by this paper
• Combining T-cell Vaccination and Application of Agonistic Anti-GITR mAb (DTA-1) Induces Complete Eradication of HPV Oncogene Expressing Tumors in Mice

  2010cited by this paper
• Mature B Cells Are Critical to T-cell-mediated Tumor Immunity Induced by an Agonist Anti-GITR Monoclonal Antibody

  2010cited by this paper
• CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

  2010cited by this paper
• Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR.

  2010cited by this paper
• CD8 T Cell-Intrinsic GITR Is Required for T Cell Clonal Expansion and Mouse Survival following Severe Influenza Infection

  2010cited by this paper
• Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals

  2010cited by this paper
• Glucocorticoid-Induced TNFR-Related (GITR) Protein and Its Ligand in Antitumor Immunity: Functional Role and Therapeutic Modulation

  2010cited by this paper
• Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation

  2010cited by this paper
• Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.

  2010cited by this paper
• Control of immunity by the TNFR-related molecule OX40 (CD134).

  2010cited by this paper
• OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis

  2009cited by this paper
• Key Role of the GITR/GITRLigand Pathway in the Development of Murine Autoimmune Diabetes: A Potential Therapeutic Target

  2009cited by this paper
• T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.

  2009cited by this paper
• Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy

  2009cited by this paper
• Glucocorticoid‐induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen‐specific CD8+ T cells with tumor regression

  2009cited by this paper
• Endogenous 4-1BB Ligand Plays a Critical Role in Protection from Influenza-Induced Disease1

  2009cited by this paper
• GITR: a modulator of immune response and inflammation.

  2009cited by this paper
• Structural basis for ligand-mediated mouse GITR activation

  2008cited by this paper
• Glucocorticoid-induced Tumor Necrosis Factor Receptor Negatively Regulates Activation of Human Primary Natural Killer (NK) Cells by Blocking Proliferative Signals and Increasing NK Cell Apoptosis*

  2008cited by this paper
• Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling.

  2008cited by this paper
• Evolution of GITRL immune function: Murine GITRL exhibits unique structural and biochemical properties within the TNF superfamily

  2008cited by this paper
• OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

  2008cited by this paper
• Pivotal Roles of CD4+ Effector T cells in Mediating Agonistic Anti-GITR mAb-Induced-Immune Activation and Tumor Immunity in CT26 Tumors

  2007cited by this paper
• Genetic and pharmacological inhibition of GITR‐GITRL interaction reduces chronic lung injury induced by bleomycin instillation

  2007cited by this paper
• Cancer immunoediting by GITR (glucocorticoid‐induced TNF‐related protein) ligand in humans: NK cell/tumor cell interactions

  2007cited by this paper
• Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.

  2006cited by this paper
• Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL).

  2006cited by this paper
• Proinflammatory Role of Glucocorticoid-Induced TNF Receptor-Related Gene in Acute Lung Inflammation1

  2006cited by this paper
• CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

  2006cited by this paper
• GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice

  2006cited by this paper
• Glucocorticoid-Induced TNF Receptor Family Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma Differentiation Antigens and Enhances Antitumor Immunity1

  2006cited by this paper
• Role of glucocorticoid‐induced TNF receptor family gene (GITR) in collagen‐induced arthritis

  2005cited by this paper
• Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.

  2005cited by this paper
• TNF/TNFR family members in costimulation of T cell responses.

  2005cited by this paper
• In Vivo Kinetics of GITR and GITR Ligand Expression and Their Functional Significance in Regulating Viral Immunopathology

  2005cited by this paper
• Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells

  2005cited by this paper
• Glucocorticoid-Induced TNF Receptor Functions as a Costimulatory Receptor That Promotes Survival in Early Phases of T Cell Activation1

  2005cited by this paper
• Regulation of autoimmune diabetes by non‐islet‐specific T cells — a role for the glucocorticoid‐induced TNF receptor

  2004cited by this paper
• Glucocorticoid‐induced TNF receptor family gene (GITR) knockout mice exhibit a resistance to splanchnic artery occlusion (SAO) shock

  2004cited by this paper
• Cutting Edge: Ligation of the Glucocorticoid-Induced TNF Receptor Enhances Autoreactive CD4+ T Cell Activation and Experimental Autoimmune Encephalomyelitis1

  2004cited by this paper
• Costimulation via Glucocorticoid-Induced TNF Receptor in Both Conventional and CD25+ Regulatory CD4+ T Cells1

  2004cited by this paper
• Expression and function of 4‐1BB during CD4 versus CD8 T cell responses in vivo

  2004cited by this paper
• GITR Activation Induces an Opposite Effect on Alloreactive CD4+ and CD8+ T Cells in Graft-Versus-Host Disease

  2004cited by this paper
• Engagement of Glucocorticoid-Induced TNFR Family-Related Receptor on Effector T Cells by its Ligand Mediates Resistance to Suppression by CD4+CD25+ T Cells

  2004cited by this paper
• Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells

  2004cited by this paper
• Frontline: GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations

  2004cited by this paper
• Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells

  2003cited by this paper
• Regulation of Murine Inflammatory Bowel Disease by CD25+ and CD25− CD4+ Glucocorticoid-Induced TNF Receptor Family-Related Gene+ Regulatory T Cells1

  2003cited by this paper
• Role of GITR in activation response of T lymphocytes.

  2002cited by this paper
• Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance

  2002cited by this paper
• CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.

  2002cited by this paper
• Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand*

  1999cited by this paper
• Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR.

  1999cited by this paper
• A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis.

  1997cited by this paper
• Inducible T cell antigen 4-1BB. Analysis of expression and function.

  1993cited by this paper
• Down-regulation of the antitumor immune response.

  1985cited by this paper

• Radiotherapy Improves Antitumor Immunity by Inducing Immunogenic Cell Death in Breast Cancer Patients

  2025cites this paper
• First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors

  2025cites this paper
• Advances in Cell and Immune Therapies for Melanoma

  2025cites this paper
• Immunotherapy for colorectal cancer

  2024cites this paper
• Influence of Microbiota on Tumor Immunotherapy

  2024cites this paper
• Deciphering Regulatory T-Cell Dynamics in Cancer Immunotherapy: Mechanisms, Implications, and Therapeutic Innovations.

  2024cites this paper
• Herpesvirus entry mediator as a potential biomarker in breast cancer compared with conventional cytotoxic T‑lymphocyte‑associated antigen 4

  2023cites this paper
• Quantitative systems pharmacology model of GITR‐mediated T cell dynamics in tumor microenvironment

  2023cites this paper
• Comparative evaluation of antitumor effects of TNF superfamily costimulatory ligands delivered by mesenchymal stem cells.

  2023cites this paper
• GITR activation ex vivo impairs CD8 T cell function in people with HIV on antiretroviral therapy

  2023cites this paper
• Combination of local radiotherapy and anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) therapy augments PD-L1 blockade-mediated anti-tumor effects in murine breast cancer model.

  2023cites this paper
• Prognostic and predictive significance of GITR in metastatic renal cell carcinoma.

  2023cites this paper
• Peripheral changes in T cells predict efficacy of anti-PD-1 immunotherapy in non-small cell lung cancer.

  2023cites this paper
• Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers

  2023cites this paper
• Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment

  2022cites this paper
• Basics of immunooncology and immunotherapy in oncology

  2022cites this paper
• The role of CD101-expressing CD4 T cells in HIV/SIV pathogenesis and persistence

  2022cites this paper
• Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism

  2022cites this paper
• An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy

  2022cites this paper
• Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma

  2022cites this paper
• Inflammation and tumor progression: signaling pathways and targeted intervention

  2021cites this paper
• Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy

  2021cites this paper
• Multiple mechanisms for TRAF3-mediated regulation of the T cell costimulatory receptor GITR

  2021influential citation
• Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies

  2021cites this paper
• Co-stimulatory agonists: An insight into the immunotherapy of cancer

  2021influential citation
• Tumor resident regulatory T cells.

  2021cites this paper
• The role of regulatory T cells in the pathogenesis and treatment of prostate cancer.

  2021cites this paper
• Empirical and Rational Design of T Cell Receptor-Based Immunotherapies

  2021cites this paper
• First‐in‐human phase 1 study of MK‐1248, an anti–glucocorticoid‐induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors

  2020influential citation
• Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review

  2020cites this paper
• Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors

  2020cites this paper
• Development of a robust reporter gene assay for measuring the bioactivity of OX40-targeted therapeutic antibodies.

  2020cites this paper
• Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors

  2020cites this paper
• Determinants of Resistance to Checkpoint Inhibitors

  2020cites this paper
• T-cell agonists in cancer immunotherapy

  2020cites this paper
• The Immunobiology of Transplant Rejection and Acceptance

  2020cites this paper
• Identification of CTLA-4 associated with tumor microenvironment and competing interactions in triple negative breast cancer by co-expression network analysis

  2020cites this paper
• Adult Immuno-Oncology: Using Past Failures to Inform the Future.

  2020cites this paper
• Overcoming Cancer Tolerance with Immune Checkpoint Blockade

  2020cites this paper
• Domain binding and isotype dictate the activity of anti-human OX40 antibodies

  2020cites this paper
• Regulatory T Cells in Cancer

  2020cites this paper
• In vitro assays for effector T cell functions and activity of immunomodulatory antibodies.

  2020cites this paper
• Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery

  2019cites this paper
• Pre-immunization of donor lymphocytes with GITR agonistic antibody enhances antitumor immunity in autologous hematopoietic stem cell transplantation.

  2019cites this paper
• Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials

  2019cites this paper
• Emerging Roles of Th9 Cells as an Anti-tumor Helper T Cells

  2019influential citation
• Characterization and Comparison of GITR Expression in Solid Tumors

  2019cites this paper
• Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody

  2019cites this paper
• Stimulating T Cells Against Cancer With Agonist Immunostimulatory Monoclonal Antibodies.

  2019cites this paper
• The TNF-TNFR Family of Co-signal Molecules.

  2019cites this paper
• Rational design of anti-GITR-based combination immunotherapy

  2019cites this paper
• Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

  2019cites this paper
• Advanced stage melanoma therapies: Detailing the present and exploring the future.

  2019cites this paper
• NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.

  2019cites this paper
• Regulatory T cells in the treatment of disease

  2018cites this paper
• Identification of Chicken GITR and GITR Ligand, Proof of Their Mutual Interaction, and Analysis of Chicken GITR Tissue Distribution by a Novel Antibody That Reveals Expression on Activated T Cells and Erythrocytes

  2018cites this paper
• Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions

  2018cites this paper
• Immunotherapy for cervical cancer: Can it do another lung cancer?

  2018cites this paper
• Influenza-Activated ILC1s Contribute to Antiviral Immunity Partially Influenced by Differential GITR Expression

  2018cites this paper
• Next generation immune-checkpoints for cancer therapy.

  2018cites this paper
• Structure-Function Analysis of Immune Checkpoint Receptors to Guide Emerging Anticancer Immunotherapy.

  2018cites this paper
• Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy

  2018cites this paper
• Immunoengineering through cancer vaccines – A personalized and multi‐step vaccine approach towards precise cancer immunity

  2018cites this paper
• Anti-glucocorticoid-induced Tumor Necrosis Factor–Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects

  2018cites this paper
• Current Options and Future Directions in Immune Therapy for Glioblastoma

  2018cites this paper
• Bayesian Network Marker Selection via the Thresholded Graph Laplacian Gaussian Prior.

  2018cites this paper
• Immunomodulation with Adjuvants and Cytokines

  2018cites this paper
• Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer

  2018cites this paper
• Anti-GITR Antibody Treatment Increases TCR Repertoire Diversity of Regulatory but not Effector T Cells Engaged in the Immune Response Against B16 Melanoma

  2017cites this paper
• Joint Action of the Nano-sized System of Small Non-coding RNAs with DDMC Vector and Recombinant IL-7 Reprograms A-549 Lung Adenocarcinoma Cells into CD4 + Cells

  2017cites this paper
• A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist

  2017cites this paper
• Targeted Therapies and Immunotherapy in Prostate Cancer

  2017cites this paper
• Immunothérapie non-spécifique du cancer de la vessie : développement de nouvelles approches basées sur la combinaison d'agents thérapeutiques

  2017cites this paper
• MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential

  2017cites this paper
• Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment

  2017cites this paper
• Enhanced immune‐modulatory effects of thalidomide and dexamethasone co‐treatment on T cell subsets

  2017cites this paper
• Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity

  2017cites this paper
• Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.

  2017cites this paper
• Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.

  2017cites this paper
• GITR: A Modulator of Regulatory and Effector T‐Cell Activity, Crucial in Tumour Rejection and Autoimmune Diseases

  2017cites this paper
• Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein

  2017cites this paper
• Biomarkers of prognosis and toxicity for metastatic melanoma patients treated with ipilimumab

  2017cites this paper
• Immunotherapy for advanced melanoma: future directions.

  2016cites this paper
• Emerging Opportunities and Challenges in Cancer Immunotherapy

  2016cites this paper
• TH9 cells in anti-tumor immunity

  2016cites this paper
• Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.

  2016cites this paper
• Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium

  2016cites this paper
• The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice

  2016cites this paper
• Cancer immunotherapy: the beginning of the end of cancer?

  2016cites this paper
• Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma

  2016cites this paper
• Modulation of tumor immunity: a patent evaluation of WO2015026684A1

  2016cites this paper
• GITR drives TH9-mediated antitumor immunity

  2016cites this paper
• Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.

  2016cites this paper
• Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.

  2016cites this paper
• Combination of immune stimulatory strategies to promote anti-tumour immunity

  2016influential citation
• A novel murine GITR ligand fusion protein induces antitumor activity as a monotherapy, which is further enhanced in combination with an OX40 agonist

  2016cites this paper
• GITR+ regulatory T cells in the treatment of autoimmune diseases.

  2015cites this paper
• Glucocorticoid-induced tumor necrosis factor receptor–related protein co-stimulation facilitates tumor regression by inducing IL-9–producing helper T cells

  2015cites this paper
• Evolving synergistic combinations of targeted immunotherapies to combat cancer

  2015cites this paper
• Glucocorticoid-Induced Tumour Necrosis Factor Receptor-Related Protein: A Key Marker of Functional Regulatory T Cells

  2015cites this paper